You are here
Therapeutic strategies in multiple sclerosis: A focus on neuroprotection and repair and relevance to schizophrenia
Matilde Inglese, Maria Petracca
Schizophrenia Research, Available online 2 June 2014
Multiple sclerosis is the leading nontraumatic cause of neurologic disability in young adults. The need to prevent neurodegeneration and promote repair in multiple sclerosis (MS) has gained increasing interest in the last decade leading to the search and development of pharmacological agents and non-pharmacologic strategies able to target not only the inflammatory but also the neurodegenerative component of the disease. This paper will provide an overview of the therapeutics currently employed in MS, with a focus on their potential neuroprotective effects and on the MRI methods employed to detect and monitor in-vivo neuroprotection and repair and the relevance of this information to schizophrenia investigation and treatment.
Matilde Inglese and Maria Petracca provide a thoughtful review of the currently available disease modifying agents for relapsing MS and their potential neuroprotective effects and implications for progressive MS, in their review “Therapeutic strategies in multiple sclerosis: A focus on neuroprotection and repair and relevance to schizophrenia.” The authors review the advanced MR imaging techniques of both gray and white matter that may support neuroprotective effects in these agents or other investigational agents. Drawing a parallel with the inflammatory and neurodegenerative features of schizophrenia, the authors highlight potential application of work done in MS to the field of schizophrenia, and vice versa. As the options for treatment of relapsing MS become more varied, our focus on progressive MS must sharpen, including the analysis of existing agents for potential neuroprotective effects, as described here.